# OnCo record tg4050 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tg4050/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tg4050" ;
  schema:name "TG4050"@en ;
  schema:description "TG4050 is an experimental individualised neoantigen therapeutic vaccine from Transgene, in phase 2 trials for HPV-negative head and neck squamous cell carcinoma and ovarian cancer."@en ;
  schema:url <https://onco.cc/drugs/tg4050/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.transgene.com/tg4050/>, <https://clinicaltrials.gov/search?intr=TG4050> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Individualised neoantigen therapeutic vaccine (myvac platform)" ;
  onco:cancers <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/>, <https://onco.cc/cancers/ovarian/> ;
  onco:companies <https://onco.cc/companies/transgene/> ;
  onco:trials <https://onco.cc/trials/nct04183166/>, <https://onco.cc/trials/nct03839524/> .